Company code: Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) company abbreviation: Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) Guangxi Wuzhou Zhongheng Group Co.Ltd(600252)
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should go to www.sse.com com. cn. The website carefully reads the full text of the annual report. 2. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 3. All directors of the company attend the board meeting. 4. YONGTUO Certified Public Accountants (special general partnership) has issued a standard unqualified audit report for the company. 5. The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
Audited by YONGTUO Certified Public Accountants (special general partnership), Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) (hereinafter referred to as “the company”) achieved a net profit of 17316628920 yuan in 2021, including 30691869492 yuan of net profit attributable to shareholders of listed companies, 11492577799 yuan of surplus reserve, 248266131216 yuan of undistributed profit at the beginning of the year and 29456795084 yuan of profit distribution in 2020 in the current period, In 2021, the actual distributable profit of the company was 238008627825 yuan, and the actual distributable profit of the parent company was 171741366030 yuan.
According to the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 1 – standardized operation, the company law, the decision on Amending Several Provisions on cash dividends of listed companies and the articles of association, this dividend distribution is planned to distribute a cash dividend of 0.27 yuan (including tax) for every 10 shares based on 3425208704 shares after deducting treasury shares from the total share capital at the end of 2021, The total amount of cash dividends distributed to all shareholders whose equity distribution is registered is 9248063501 yuan (including tax). Capital reserve will not be converted into share capital in 2021.
The profit distribution plan for 2021 can be implemented only after being approved by the general meeting of shareholders of the company.
Section II basic information of the company
1 company profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange 6 Shandong Mining Machinery Group Co.Ltd(002526) 00252 Wuzhou Zhongheng
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Mo Hongsheng (on behalf of) Zhao Dan
Office address: No. 1, Industrial Avenue, industrial park, Wuzhou, Guangxi
Tel: 07743939022
E-mail zh6 Qifeng New Material Co.Ltd(002521) 26.com. zh6 Qifeng New Material Co.Ltd(002521) 26.com.
2. Introduction to the company’s main business in the reporting period
(I) basic development of pharmaceutical manufacturing industry
In the context of population aging, medical insurance funds are facing revenue and expenditure pressure, while China’s commercial insurance has not yet risen, and there is a shortage of payment power. Medical insurance fee control is still the main theme of the pharmaceutical industry policy. At present, the national drug volume procurement has been completed, and six rounds of coronary stents and joint implantation devices have been involved in the volume procurement. In the future, it will be extended to Chinese patent medicine and biological similar drugs. The quantity of centralized varieties increases and the price decreases significantly Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) is facing the internal and external demand of “strengthening the leader, supplementing the chain, expanding products, expanding business and seeking development”. The company will promote the transformation and upgrading of the pharmaceutical industry with policies, strive to become an integrator of medical and health resources and realize Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) high-quality sustainable development. (II) industry development status
In 2021, China’s GDP for the whole year was 114367 billion yuan, an increase of 8.1% over the previous year at constant prices and an average increase of 5.1% in the two years. In the whole year, the added value of industries above designated size increased by 9.6% over the previous year, with an average growth of 6.1% in the two years. In terms of economic types, state-owned holding enterprises increased by 8.0%, joint-stock enterprises increased by 9.8%, foreign-invested enterprises and enterprises invested by Hong Kong, Macao and Taiwan increased by 8.9%, and private enterprises increased by 10.2%. The annual consumer price index (CPI) rose by 0.9% over the previous year, of which medical care rose by 0.4% (the above data comes from the preliminary accounting of the National Bureau of statistics, and the specific 2021 statistical bulletin has not been released yet).
(III) cyclical characteristics
The pharmaceutical industry has strong demand rigidity, less correlation with Macro-economy and weak industry periodicity. The main factors affecting the demand for medicine are the population and population structure. With the intensification of population aging, the demand for medicine market will continue to expand. Under the background of escalating consumption, people pay more attention to health care and their medical affordability is improved, the demand of China Meheco Group Co.Ltd(600056) medical market will also usher in explosive growth in the next few years.
(IV) industry position of the company
The company is a national high-tech enterprise with pharmaceutical as its core business and extended sectors such as medical protective articles, healthy food and traditional Chinese medicine planting. It has field and product advantages, stable business style and remarkable profitability. A complete business model of pharmaceutical industry chain has been formed, integrating scientific research, production, sales and service. The pharmaceutical manufacturing industry of the company ranks among the top 100 enterprises in China’s pharmaceutical industry and has high brand awareness, reputation and loyalty in the industry. It is China Meheco Group Co.Ltd(600056) industrial top 100 enterprises and Guangxi leading pharmaceutical manufacturer. Focusing on the requirements of high-quality development, the company’s management level has been further improved, and its brand value has been recognized by the market, ranking 19th in the “top 100 list of China Meheco Group Co.Ltd(600056) enterprises in 2020″, “79th in the top 100 list of China Meheco Group Co.Ltd(600056) industries in 2020″ and 23rd in the “top 100 list of Chinese patent medicine enterprises in 2021” Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) , Wuzhou pharmaceutical were selected into the “2021 China brand value evaluation list”, and ranked 10th and 12th respectively in terms of brand value in the “China Time-honored Brands” list.
Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) takes the inheritance and innovation in the field of medical, medical and health as its responsibility, takes improving human life quality experience as its development mission, improves people’s quality of life, inherits health culture, advocates the combination of medical care and health care, and benefits the public Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) takes pharmaceutical manufacturing as the core leading industry and holds 11 important subsidiaries. Among them, there are three national high-tech enterprises and one listed company (Chongqing Chongqing Lummy Pharmaceutical Co.Ltd(300006) , stock code: Chongqing Lummy Pharmaceutical Co.Ltd(300006) ). Its business covers medical protection, food manufacturing, pharmaceutical research and development, pharmaceutical circulation, traditional Chinese medicine industry, daily chemical industry and other fields. Its main business can be divided into pharmaceutical and medical protection products manufacturing, food manufacturing, traditional Chinese medicine, pharmaceutical circulation and daily chemical industry. The business entities and information of each business segment are as follows:
1. Manufacturing of medicine and medical protective articles
(1) Wuzhou pharmaceutical, a subsidiary of the company, is mainly engaged in the production and manufacturing of Chinese patent medicine. After nearly a hundred years, Wuzhou pharmaceutical has developed into a modern pharmaceutical production enterprise. It is a national high-tech enterprise. It is one of the top 100 China Meheco Group Co.Ltd(600056) industrial enterprises, a leading pharmaceutical production enterprise in Guangxi and a large traditional Chinese medicine injection production enterprise in South China. It has been recognized as a “national intellectual property demonstration enterprise”. Wuzhou pharmaceutical has rich resources and outstanding advantages, with 14 categories, 216 varieties of dosage forms and 308 drug approval numbers. Among them, there are 7 national patented products and 106 varieties included in the 2020 edition of Chinese Pharmacopoeia. The main products of Wuzhou pharmaceutical include Xueshuantong for injection (freeze-dried), Zhonghua Dieda pill, Fuyanjing capsule, shilitong tablet, yanjianning tablet, Angongniuhuang pill, snake gall Chuanbei liquid, fluorescein sodium injection, etc. the treatment scope of products includes cardio cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system and other fields. Among them, Xueshuantong (freeze-dried) for injection for cardiovascular and cerebrovascular diseases is the core drug variety of Wuzhou pharmaceutical. Zhonghua Dieda pill is the original research and production of Wuzhou pharmaceutical, the product of national invention patent and the variety of national pharmacopoeia. Xueshuantong for injection (freeze-dried), Zhonghua Dieda pill, Fuyanjing capsule and shilitong tablet were rated as high-tech products. Pharmaceutical companies have strong R & D strength and effective patents
121, including 97 invention patents, 10 utility model patents and 14 design patents. The invention patent “a traditional Chinese medicine compound preparation for treating hepatitis” won the 22nd China Patent Excellence Award.
Wuzhou pharmaceutical also has trademarks such as “Zhonghua”, “Chenzhong” and “Zhongheng”. The exclusive trademark “Zhonghua” brand of Chinese patent medicine products has won the honorary title of “China Time-honored Brand” awarded by the Ministry of Commerce of the people’s Republic of China. It is also the only enterprise in the China Meheco Group Co.Ltd(600056) field approved to use the “Zhonghua” named trademark. (2) The company’s subsidiary Chongqing Lummy Pharmaceutical Co.Ltd(300006) was established in 1999 and was listed on the growth enterprise market of Shenzhen Stock Exchange on October 30, 2009 with the stock code of Chongqing Lummy Pharmaceutical Co.Ltd(300006) . It is one of the first 28 companies on the growth enterprise market and the first listed company in Chongqing Chongqing Lummy Pharmaceutical Co.Ltd(300006) continuously undertook the major special scientific research projects of science and technology in the eleventh five year plan, the Twelfth Five Year Plan and the thirteenth five year plan. In 2019, it was recognized as the “national technological innovation demonstration enterprise” by the Ministry of industry and information technology of the people’s Republic of China, won the “honor list of excellent enterprises in the pharmaceutical industry in the 70th anniversary of the founding of China – benchmark enterprise”, and was rated as the Key Laboratory of industry and informatization in Chongqing by Chongqing Municipal Commission of economy and information technology in 2021 Chongqing Lummy Pharmaceutical Co.Ltd(300006) its main business is pharmaceutical manufacturing, and its products are rich in varieties. Its main products cover special specialties (mainly including anti-tumor drugs, digestive system drugs, parenteral nutrition drugs), anti infection and other fields Chongqing Lummy Pharmaceutical Co.Ltd(300006) main products include nano carbon suspension injection (kanalin) (hereinafter referred to as “kanalin”) and esmeprazole enteric coated capsule (lemesu) (hereinafter referred to as “lemesu”). Among them, kanalin is the only lymphatic tracer approved by CFDA. It has won many honorary titles such as ” China National Chemical Engineering Co.Ltd(601117) excellent product brand of original developed drugs and patented drugs in the pharmaceutical industry” for four consecutive years, ” China National Chemical Engineering Co.Ltd(601117) excellent product brand of drugs in other disciplines in the pharmaceutical industry” for two consecutive years, and “single champion product in the manufacturing industry (20192021)” and “China industry university research cooperation innovation and Promotion Award in 2021″, The product has good lymphatic tropism and can achieve the purpose of lymphatic tracing. It can also be used as a drug carrier to load drugs into the lymphatic system and achieve the purpose of lymphatic targeted therapy. As the first domestic oral preparation of Esme omeprazole on the market, it belongs to the national medical insurance variety. It has won the title of ” China National Chemical Engineering Co.Ltd(601117) excellent product brand of digestive system in pharmaceutical industry” for four consecutive years and the honorary title of ” China National Chemical Engineering Co.Ltd(601117) excellent product brand of original and patented drugs in pharmaceutical industry” for two consecutive years. It was approved by China industry university research cooperation innovation and Promotion Award Office in January 2019, Laimeishu won the “Excellence Award for innovation achievements of China’s industry university research cooperation in 2019”. As a new generation of proton pump inhibitor (PPI), lemesu has rapid, lasting and stable inhibition of gastric acid, and has a high HP eradication rate.
(3) Zhongheng medical, a subsidiary of the company, was established at the critical time of covid-19 pneumonia. Zhongheng medical is mainly engaged in the R & D, production and sales of medical devices, labor protection articles, protective articles, disinfection articles, medical articles, patient medical reagents and other products. The main products are medical protective masks, medical surgical masks, disposable medical masks, medical disposable protective clothing, medical infrared forehead thermometer, medical isolation eye masks, disposable isolation clothes, medical isolation masks and other epidemic prevention materials.
2. Food manufacturing sector
Shuangqian industry, a subsidiary of the company, is a modern production enterprise integrating R & D, production and sales. It is committed to the protection and inheritance of the production technology of guiling paste. It has pioneered the “shuangqian” brand of easy to pull can guiling paste and plastic bowl guiling paste in the country. It has become a pioneer in the industrialization of guiling paste products and successfully cultivated the authentic brand of Wuzhou guiling paste – “shuangqian” brand. Shuangqian industry has continuously expanded its product types, including guiling paste, Guiling treasure, guiling paste powder, Liubao tea, nixing pottery, instant porridge, beverages and solid drinks, grain and oil, snail powder and other products. The “shuangqian” brand guiling paste has won the title of “Guangxi famous brand product” for more than 20 years; In 2007, it was rated as “intangible cultural heritage of Guangxi”; “Shuangqian” brand can turtle Ling paste and plastic bowl turtle Ling paste won the “Hundred Flowers Award for new products in Guangxi” and “new products of science and technology in Guangxi” respectively. Shuangqian industry presided over the application of “Wuzhou Guiling ointment”, which was approved as a geographical indication protection product of the people’s Republic of China and approved by Wuzhou municipal government to use the special logo for geographical indication protection products; In 2010, shuangqian Guiling cream won the silver award of the first China Intangible Cultural Heritage Expo; In 2011, “shuangqian” trademark won the title of “China Time-honored Brand”. In 2021, Wuzhou Guiling cream was selected into the fifth batch of national intangible cultural heritage catalogue, shuangqian industry was recognized as the protection unit of the National Intangible Cultural Heritage Representative project Guiling cream preparation technology, and the title of “the third batch of recognized high-tech enterprises” at the national level.
3. Chinese herbal medicine
Guangxi Wuzhou Zhongheng Group Co.Ltd(600252) implement the requirements of “Chinese medicine enterprises self build or jointly build stable Chinese medicine production bases in the form of orders” advocated in the opinions of the CPC Central Committee and the State Council on promoting the inheritance, innovation and development of traditional Chinese medicine, take the opportunity of industrial poverty alleviation and rural revitalization, actively explore the combination of modern agricultural production technology and Chinese medicine planting, and invest in building a poverty alleviation and innovation demonstration base of Chinese medicine planting industry, mainly planting liangfencao, kuxuanshen There are more than 20 varieties of Lysimachia christinae, Baibu, wuzhimaotao, Liuzhou Liangmianzhen Co.Ltd(600249) and other varieties. At the same time, we will build the processing, storage, logistics and trade base of traditional Chinese medicine, strive to build the base into a national demonstration base of traditional Chinese medicine planting and even a national demonstration base of Southern medicine industry, promote the group to realize the integrated development of primary, secondary and tertiary industries, and finally build a large-scale industrial cluster of traditional Chinese medicine, so as to contribute to the development of the national traditional Chinese medicine industry.
